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Abstract The suiphydryl reagent phenylarsine oxide (PAO) (1 
tiM) inhibited completely formation of inositol phosphates in 
human platelets induced by collagen or by cross-linking of the 
platelet low affinity Fc receptor, FcyRIIA, but did not alter the 
response to the G protein receptor agonist hrombin. PAO also 
inhibited completely tyrosine phosphorylation of PLCy2 in colla- 
gen and Fc3~RIIA-stimulated cells, although tyrosine phosphoryl- 
ation of other proteins including the tyrosine kinase syk was 
relatively unaffected. PAO (1 ttM) also inhibited completely 
tyrosine phosphorylation of PLCy1 induced by platelet derived 
growth factor (PDGF) in NIH-3T3 fibroblasts but only partially 
reduced phosphorylation of the PDGF receptor. These results 
provide further evidence that collagen and FcyRIIA cross-linking 
activate platelets through a pathway distinct from that used by 
thrombin and suggest hat PAO may be a selective inhibitor of 
PLCy relative to PLC ~ isozymes. 
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I. Introduction 
Phenylarsine oxide (PAO) is a trivalent arsenical compound 
which induces a wide spectrum of effects in biologic systems 
through covalent modification of thiol groups [1]. In particular, 
PAO has been reported to inhibit a number of transmembrane 
signalling pathways that involve tyrosine phosphorylation in- 
cluding insulin-mediated activation of p21 ras in fibroblasts [2] 
and activation of T-lymphocytes through the T-cell antigen 
receptor complex [3,4]. PAO also inhibits tyrosine phosphoryl- 
ation of PLCyl induced by cross-linking of the high affinity 
receptor for immunoglobulin E on mast cells [5] and by cross- 
linking of anti-CD3 monoclonal antibodies in T-lymphocytes 
[6]. 
There is considerable evidence for the role of tyrosine phos- 
phorylation i  the early events associated with platelet activa- 
tion [7-12]. For example, we and others reported recently that 
collagen and cross-linking of the platelet low-affinity IgtG re- 
ceptor FcyRIIA (CD32) stimulate PLC activity through atyro- 
sine kinase dependent pathway involving tyrosine phosphoryla- 
tion of PLCy2 [11,12]. In contrast, the G protein receptor 
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stimuli thrombin and U46619, a thromboxane mimetic, induce 
little or no tyrosine phosphorylation f PLCy2 [11,12]. The 
molecular events which underlie phosphorylation f PLCy2 by 
collagen or by FcyRIIA-crosslinking are not established. 
The aim of the present study was to investigate further 
whether FcyRIIA cross-linking and collagen induce platelet 
activation through a common mechanism. The effect of PAO 
on responses induced by FcyRIIA cross-linking and collagen 
has been compared in view of the recent report hat the sulphy- 
dryl reagent inhibits platelet activation by collagen [13]. The 
results illustrate that PAO inhibits platelet activation induced 
by FcyRIIA cross-linking or by collagen through inhibition of 
tyrosine phosphorylation f PLCy2. PAO also inhibits tyrosine 
phosphorylation f PLCy 1 in NIH-3T3 fibroblasts activated by 
PDGF suggesting that it may be a general inhibitor of PLCy 
isoforms. 
2. Materials and methods 
2.1. Materials 
Antiserum against PLCy 1 and the anti-phosphotyrosine monoclonal 
antibody (mAb), 4G10, were purchased from Upstate Biotechnology 
Inc. (TCS Biologicals Ltd., Bucks., UK). Rabbit antiserum raised 
against residues 461 to 481 and 1218 to 1239 of PLCy2 was prepared 
as described [14]. mAb IV.3, specific for FcyRIIA, was purchased from 
Madarex Inc. (New Hampshire, USA). Collagen was from Nycomed 
(Munich, Germany). Indomethacin, Nonidet P-40 (NP-40), thrombin, 
Tween-20 and sheep F(ab')2 raised against mouse IgG (M-1522) were 
purchased from Sigma (Poole, Dorset, UK). PAO was purchased from 
Aldrich. An anti-syk rabbit polyclonal antibody raised against a pol- 
yhistidine fusion protein containing amino acids 257-352 within the 
linker region of syk was purchased from Santa Cruz, California. Poly- 
vinylidene difluoride (PVDF) western blotting membrane was from 
Bio-Rad (Herts., UK). Horseradish peroxidase-conjugated sh ep anti- 
mouse Ig (NA931) and horseradish peroxidase-conjugated donkey 
anti-rabbit Ig (NA934), ECL reagents, and myo-[3H]inositol (18.2 Ci/ 
mmol) were from Amersham International (Cardiff, UK). NIH-3T3 
cells were from the Dept. of Pathology, Oxford University. All other 
reagents were of analytical grade. 
2.2. Preparation of human platelets 
Human blood was taken from drug-free volunteers on the day of the 
experiment. Platelet-rich plasma was obtained by centrifugation at
200 x g for 20 min. Platelets were isolated from platelet-rich plasma by 
centrifugation at 1000 x g for 10 min in the presence ofprostacyclin (0.1 
pg/ml). Platelets were resuspended in 10 ml of a modified Tyrodes- 
HEPES buffer (134 mM NaCI, 0.34 mM Na2HPO4, 2.9 mM KC1, 
12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, 1mM MgCI 2, pH 
7.3) in the presence of prostacyclin (0.1 pg/ml) and recentrifuged at 
1000 × g for 10 min before resuspension at a concentration f 5 x 108 
cells/ml in the above buffer. For experiments involving measurement 
of [3H]inositol phosphates, platelets were initially resuspended in 1 ml 
of buffer following separation from plasma nd labelled with 50 ,uCi 
[3H]inositol for 3 h. At the end of the incubation, the volume of buffer 
was adjusted to 10 ml and platelets were centrifuged again at 1000 xg 
for 10 min and resuspended in the Tyrodes-HEPES buffer containing 
indomethacin (10/.tM). Platelets were left 30 min and all experiments 
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were carried out at 37°C in an aggregometer with continuous tirring 
(800 rpm). 200" 
2.3. Measurement of inositol phosphates 
[3H]InositoMabelled platelets were resuspended in the above buffer 
to which 10 mM LiCI had been added in order to inhibit conversion 
of inositol phosphates to inositol. Platelet suspensions (200/A) were 
stimulated for 5 min at 37°C under continuous tirring and reactions 
stopped by transfer to 1 ml of chloroform/methanol/HC1 (50: 100: 1, by 
vol). [3H]Inositol phosphates (i.e. inositol mono-, bis- and tris-phos- 
phates) were separated by Dowex anion exchange chromatography as 
described previously [15]. 
2.4. Immunoblotting 
An equal volume of Laemmli sample buffer was added and samples 
heated for 5 min at 95°C. Proteins were separated by 10% SDS-PAGE 
and transferred to PVDF blotting membranes u ing a semi-dry transfer 
system (120 min, 15V). Membranes were incubated for 30 min at room 
temperature with 10% BSA in TBS-T (20 mM Tris, 137 mM NaCI, 0.1% 
Tween-20, pH 7.6), before probing for 1 h at room temperature with 
the primary antibodies 4G10 (anti-phosphotyrosine antibody), anti- 
PLCyl or anti-PLC72. Membranes were washed five times in TBS-T 
and bound primary antibody was detected by incubation for 1 h with 
horseradish-peroxidase-conjugated she panti-mouse Ig or donkey 
anti-rabbit Ig as secondary antibody. Membranes were washed in TBS- 
T and treated with ECL reagents before exposure to ECL-Hyperfilm. 
Where required, blots were stripped of bound antibody by washing in 
TBS-T containing 2% SDS at 80°C for 40 min. Membranes were 
washed three times with TBS-T and reprobed with secondary antibody 
to confirm removal of the primary antibody. Membranes were then 
probed with a different primary antibody. 
2.5. Immunoprecipitation 
Cells (1 × 109 cells/ml) were lysed on ice for 30 min with an equal 
volume of ice-cold lysis buffer (1% NP-40, 10 mM EDTA, 2 mM 
EGTA, 2 mM Na3VO4, 1 mM PMSF, 300 mM NaC1, 10 mM Tris, pH 
7.3). Insoluble cell debris was removed by centrifugation at 11,600 × g 
for 15 min and supernatant pre-cleared with 25/A of protein A-Sepha- 
rose CL-4B which had been hydrated in TBS-T containing 10% BSA. 
Samples were divided and incubated with 3 ktl of rabbit anti-PLC72 
antiserum or 5/~g of anti-syk antiserum for 90 min before addition of 
25/zl of protein A-Sepharose CL-4B. After a further incubation of 60 
min, the protein A-Sepharose CL-4B was precipitated by centrifugation 
at 11,600 x g for 30 s and washed five times in 1 ml of TBS-T containing 
1 mM PMSF, 1 mM Na3VO 4 and 1 mM EDTA. Immunoprecipitated 
proteins were subjected to SDS-PAGE, transferred to PVDF mem- 
brane and immunoblotted asdescribed above. For the FcyRIIA im- 
munoprecipitation, solubilized samples were incubated with 1 /lg of 
mAb IV.3 without pre-clearing. 
2.6. Preparation of NIH-3 T3 fibroblasts 
NIH-3T3 fibroblasts were grown in Dulbecco's modified eagle me- 
dium (Gibco) supplemented with 10% fetal bovine serum in 6-well 
plates. After cells reached semi-confluence, they were twice washed with 
fresh media before stimulation with 2 nM PGDFfl for 10 rain at 37°C. 
The measurement of tyrosine phosphorylation f PLCT1 was carried 
out as described above; immunoprecipitations were performed using 
4/zg of anti-PLC$1 antiserum. 
3. Results 
3.1. PAO inhibits collagen and FcTRIIA-induced activation of 
PLC 
PAO inhibited formation of inositol phosphates induced by 
FcyRI IA cross-linking and collagen over a similar concentra- 
tion range with half maximal and maximal inhibition observed 
at ~0.1 and 1/zM PAO, respectively (Fig. 1). This was accom- 
panied by inhibition of aggregation and secretion of 5-hy- 
droxytryptamine (not shown). In contrast, PAO (0.01-1/IM) 
had no apparent effect on formation of [3H]inositol phosphates 
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Fig. 1. Effect of phenylarsine oxide (PAO) on phospholipase C activity. 
[3H]Inositol-labelled platelets were pretreated with or without various 
concentrations of PAO for 30 s and stimulated with thrombin (0.1 
unit/ml), FcTRIIA cross-linking (IV.3 [1 Hg/ml] and F(ab')2 [30/tg/ml]), 
or collagen (100/tg/ml) for 5 rain at 37°C. Formation of [3H]inositol 
phosphates was measured as described in section 2. The results are the 
mean + S.E.Mean of four experiments. Thrombin, I1; FcTRIIA cross- 
linking, A; collagen, @; basal dpm was 348 _+ 11 and each stimulus 
increased this value to 1472 + 56, 772 + 69 and 759 + 73, respectively. 
served at a concentration of 10/~M (Fig. 1). These results 
provide further evidence that FcyRI IA  cross-linking and colla- 
gen-induce platelet activation by a common pathway which is 
distinct from that utilised by thrombin. 
3.2. Effect of  PAO on protein tyrosine phosphorylation 
PAO (1/ IM) had little effect on the general pattern of tyro- 
sine phosphorylation i duced by FcyRI IA  cross-linking and 
collagen (not shown) despite the fact that this concentration 
produces complete inhibition of PLC activity. The effect of 
PAO on tyrosine phosphorylation of specific proteins was in- 
vestigated in immunoprecipitation studies. Activation of plate- 
lets by cross-linking of FcyRI IA  is associated with phosphoryl- 
ation of FcyRI IA  itself [16,17] a response that was increased 
slightly by 1/~M PAO in some but not all experiments (Fig. 2). 
This is consistent with the observation that tyrosine phospho- 
rylation of FcyRI IA  is independent of PLC [17]. Collagen and 
FcyRI IA  cross-linking induce tyrosine phosphorylation of the 
tyrosine kinase syk [18,19] and this response this is maintained 
in the presence of 0.1 10 /IM PAO (Fig. 3) demonstrating 
independence from PLC activity. In contrast, PAO inhibits 
completely tyrosine phosphorylation of PLC72 induced by 
cross-linking of FcTRI1A or by collagen over the same concen- 
tration range as that for inhibition of formation of inositol 
phosphates (Fig. 3). 
3.3. PAO inhibits tyrosine phosphorylation of PLCyl  in NIH- 
3T3 cells stimulated by PDGFfl 
PAO has been reported to inhibit tyrosine phosphorylation 
of PLC71 in mast cells and T-cells following activation of the 
FcgRI receptor or the T-cell receptor complex. To our knowl- 
edge, however, there is no report of the effect of PAO on 
activation of PLC71 or PLC72 by receptors which contain 
intrinsic tyrosine kinase activity. We therefore examined the 
effect of PAO on PLCyl  tyrosine phosphorylation i PDGFfl-  
stimulated NIH-3T3 fibroblasts. Immunoprecipitation of 
PLCyl  with a specific antibody followed by western blotting 
with an antiphosphotyrosine antibody demonstrated that PAO 
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Fig. 2. Phenylarsine oxide (PAO) does not inhibit yrosine phosphoryl- 
ation of FcyRIIA. Platelets were pretreated with PAO (1 /aM) or its 
solvent for 30 s and stimulated by FcyRIIA cross-linking (IV.3 
[1/ag/ml] and F(ab')2 [30/ag/ml]) for 60 s at 37°C. FcyRIIA was im- 
munoprecipitated as escribed in section 2 and, following SDS-PAGE, 
immunoblotted for anti-phosphotyrosine. Molecular weight markers 
are shown on the left hand side. Results are representative of four 
experiments. 
inhibits completely tyrosine phosphorylation of PLC~,I by 
PDGFfl (Fig. 4). Anti-phosphotyrosine blots of whole cell ly- 
sates revealed that PDGFfl also induced marked tyrosine phos- 
phorylation of a high mwt protein (~ 180 kDa), co-migrating 
with the PDGF receptor. Phosphorylation of this band was 
inhibited slightly by PAO (Fig. 4). 
4.  D iscuss ion  
In this report, we show that PAO causes complete inhibition 
(A)  collagen + + + + 
PAO (laM) 0.1 1 10 
of PLC activation in human platelets stimulated by collagen or 
Fc~'RIIA cross-linking at a concentration of I pM and that this 
is associated with inhibition of PLC~'2 tyrosine phosphoryla- 
tion. However, at the same concentration PAO (1/.tM) had no 
significant effect on the formation of inositol phosphates in- 
duced by the G protein receptor agonist hrombin. This obser- 
vation is consistent with previous reports that thrombin induces 
little or no tyrosine phosphorylation of PLCy2 in platelets 
[12,13] and confirms that tyrosine phosphorylation f PLCy2 
does not play a significant role in thrombin-induced formation 
of inositol phosphates. The mechanism underlying potentation 
of thrombin-induced formation of inositol phosphates by a 
higher concentration of PAO (10/.tM) is not known; however, 
it is not due to increased phosphorylation of PLC~'2 (not 
shown). 
The tyrosine kinase which underlies phosphorylation of 
PLC~2 in human platelets i not established. The Fc~'RIIA has 
an immuno-receptor tyrosine activation motif (ITAM; also 
known as antigen receptor activation motif [ARAM]) in its 
cytoplasmic domain that is also present in a number of other 
immune receptors including the T-cell receptor, B-cell receptor 
and FcERI receptor [20,21]. It is now established that cross- 
linking of immune receptors leads, in a manner that is poorly 
understood, to phosphorylation f the two tyrosine residues in 
the ITAM providing asite of interaction for the related tyrosine 
kinases syk and zap-70 via their two SH2 domains [11,22]. 
There is increasing evidence for a role of syk and zap-70 in 
tyrosine phosphorylation of PLCT" isoforms induced by im- 
mune receptors. For example, crosslinking of a chimeric recep- 
tor protein containing syk as its cytosolic tail is sufficient o 
stimulate tyrosine phosphorylation f PLC~,I in rat basophilic 
FcT-RIIA + + + + 
123 
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Fig. 3. Phenylarsine oxide (PAO) inhibits tyrosine phosphorylation f PLC~'2 but not syk. Platelets were pretreated with PAO (1/aM) or its solvent 
for 30 s and stimulated by Fc~'RIIA cross-linking (IV.3 [1/ag/ml] and F(ab') 2[30/ag/ml]) or collagen (100/ag/ml) for 60 and 90 sec, respectively at
37°C. Immunoprecipitation of syk and PLCy2, and anti-phosphotyrosine immunoblotting were performed as described in section 2: (A) syk- 
immunoprecipitation and(B) PLC72-immunoprecipitation. Molecular weight markers are shown on the right hand side. The results are from one 
experiment representative of three other similar experiments. 
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Fig. 4. Phenylarsine oxide (PAO) inhibits tyrosine phosphorylation f PLCyl in N1H-3T3 cells induced by platelet derived growth factorfl (PDGFfl). 
NIH-3T3 cells were treated with PAO (1/IM) or its solvent for 30 s before stimulation with PDGFfl (2 nM) for 10 min. Part A shows whole ceils 
lysates immunoblotted forphosphotyrosine as described in section 2. Part B shows PLCy 1 immunoprecipitates probed with (i) anti-phosphotyrosine 
antibody and, following stripping, (ii) anti-PLCyl antiserum. Molecular weight markers are shown on the left hand side. Results are representative 
of three experiments. 
leukemia cells [23] while tyrosine phosphorylation of PLCy2 
and mobilisation of Ca `"+ are absent in response to receptor 
cross-linking in syk-negative B-lymphocytes [24]. It is not estab- 
lished, however, whether syk and zap-70 directly phosphorylate 
PLCy isoforms or whether intermediatory proteins, including 
other tyrosine kinases, are involved. The observation that tyro- 
sine phosphorylation f syk induced by FcyRI IA cross-linking 
is maintained in the presence of PAO demonstrates that syk 
phosphorylation is independent of PLCy2 activation. This re- 
sult is consistent with a possible role of syk in the regulation 
of PLCT2 phosphorylation. The demonstration that collagen- 
induced tyrosine phosphorylation f syk is also unaltered in the 
presence of PAO suggests that this kinase may also play a role 
in collagen-induced regulation of PLC/,2. 
Unexpectedly, PAO also inhibited tyrosine phosphorylation 
of PLCT1 in PDGF-stimulated NIH-3T3 cells, a response me- 
diated by the tyrosine kinase activity intrinsic to the PDGF 
receptor [25 27]. Taken together with the results of the present 
study and earlier reports that PAO inhibits tyrosine phospho- 
rylation of PLCyl induced by non-receptor tyrosine kinases in 
mast cells and T-cells [5,6], these observations suggest that PAO 
may be a general inhibitor of tyrosine phosphorylation of 
PLCy isoforms. The mechanism which underlies this action of 
PAO is not known. 
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